

University of New England
DUNE: DigitalUNE

Pharmaceutical Sciences Faculty Publications

Pharmaceutical Sciences Faculty Works

7-1-2019

TNF- α Differentially Regulates Cell Cycle Genes In Promyelocytic And Granulocytic HL-60/S4 Cells

Elsie C. Jacobson

Lekha Jain

Mark H. Vickers

Ada L. Olins

Donald E. Olins

See next page for additional authors

Follow this and additional works at: https://dune.une.edu/pharmsci_facpubs

 Part of the [Pharmacy and Pharmaceutical Sciences Commons](#)

Authors

Elsie C. Jacobson, Lekha Jain, Mark H. Vickers, Ada L. Olins, Donald E. Olins, Jo K. Perry, and Justin M. O'Sullivan

TNF- α Differentially Regulates Cell Cycle Genes in Promyelocytic and Granulocytic HL-60/S4 Cells

Elsie C. Jacobson,* Lekha Jain,* Mark H. Vickers,* Ada L. Olins,[†] Donald E. Olins,[†] Jo K. Perry,*¹ and Justin M. O'Sullivan*¹

*Liggins Institute, University of Auckland, Auckland, New Zealand and [†]University of New England, Portland, ME

ORCID IDs: 0000-0002-6094-5490 (E.C.J.); 0000-0003-4876-9356 (M.H.V.); 0000-0002-4418-947X (J.K.P.); 0000-0003-2927-450X (J.M.O.)

ABSTRACT Tumor necrosis factor alpha (TNF- α) is a potent cytokine involved in systemic inflammation and immune modulation. Signaling responses that involve TNF- α are context dependent and capable of stimulating pathways promoting both cell death and survival. TNF- α treatment has been investigated as part of a combined therapy for acute myeloid leukemia due to its modifying effects on all-trans retinoic acid (ATRA) mediated differentiation into granulocytes. To investigate the interaction between cellular differentiation and TNF- α , we performed RNA-sequencing on two forms of the human HL-60/S4 promyelocytic leukemia cell line treated with TNF- α . The ATRA-differentiated granulocytic form of HL-60/S4 cells had an enhanced transcriptional response to TNF- α treatment compared to the undifferentiated promyelocytes. The observed TNF- α responses included differential expression of cell cycle gene sets, which were generally upregulated in TNF- α treated promyelocytes, and downregulated in TNF- α treated granulocytes. This is consistent with TNF- α induced cell cycle repression in granulocytes and cell cycle progression in promyelocytes. Moreover, we found evidence that TNF- α treatment of granulocytes shifts the transcriptome toward that of a macrophage. We conclude that TNF- α treatment promotes a divergent transcriptional program in promyelocytes and granulocytes. TNF- α promotes cell cycle associated gene expression in promyelocytes. In contrast, TNF- α stimulated granulocytes have reduced cell cycle gene expression, and a macrophage-like transcriptional program.

KEYWORDS

Cytokine
Cell cycle
Gene regulation
Leukemia
Differentiation

Tumor necrosis factor alpha (TNF- α) is a pro-inflammatory cytotoxic cytokine (Sedger and McDermott 2014) which activates the innate immune response (Mizgerd *et al.* 2001; Striz *et al.* 2014; Francisco *et al.* 2015), induces migration (Smart and Casale 1994; Vieira *et al.* 2009) and promotes pro-inflammatory cytokine production (Shalaby *et al.* 1989; Kagoya *et al.* 2014). Dysregulation of TNF- α can be a factor in autoimmune disease (Chu *et al.* 1991; Palucka *et al.* 2005)

and anti-TNF antibodies are used to treat a range of inflammatory disorders (Feldmann 2002; Chowers and Allez 2010; Maxwell *et al.* 2015). Initially investigated as a cancer therapeutic due to its ability to promote apoptotic cell death specifically of tumor cells (Ziegler-Heitbrock *et al.* 1986), systemic TNF- α treatment has failed clinical trials as a solo cancer therapeutic due to unacceptable levels of toxicity (Roberts *et al.* 2011).

TNF- α signaling is complex with numerous and sometimes conflicting responses being modulated by interaction with two cell surface TNF- α receptors, TNFR1 and TNFR2 (Sedger and McDermott 2014). TNF- α binding can have a wide range of effects via activation of signal transduction pathways, including all three groups of mitogen activated kinases (MAPK); extracellular-signal-regulated kinases (ERKs), the cJun NH2-terminal kinases (JNKs), and the p38 MAP kinases (Sabio and Davis 2014), which each have complex regulatory effects on the cellular phenotype (Kim and Choi 2010; Plotnikov *et al.* 2011). TNF- α signaling leads to transcriptional upregulation of pro-inflammatory cytokines including *IL-6* (Shalaby *et al.* 1989) and *TNF* itself (Kagoya *et al.* 2014), resulting in pro-inflammatory feedback loops (Yarilina *et al.* 2008). Notably, TNFR1 and TNFR2 have individual and combinatorial

Copyright © 2019 Jacobson *et al.*

doi: <https://doi.org/10.1534/g3.119.400361>

Manuscript received May 17, 2019; accepted for publication June 28, 2019; published Early Online July 1, 2019.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplemental material available at Figshare: <https://doi.org/10.25387/g3.8146097>.

¹Corresponding authors: M&HS Building 505 - Bldg 505, Level 2, Room 202H, 85 Park Rd, Grafton, Auckland 1023, New Zealand. E-mail: j.perry@auckland.ac.nz. M&HS Building 505 - Bldg 505, Level 2, Room 202E, 85 Park Rd, Grafton, Auckland 1023, New Zealand E-mail: justin.osullivan@auckland.ac.nz

■ **Table 1** Details of HL-60/S4 RNA-seq datasets. Four conditions in triplicate were generated in this study, while three conditions with four replicates were analyzed from Welch *et al.* Cells were undifferentiated (promyelocyte), differentiated with ATRA (granulocyte) or TPA (macrophage). Promyelocytes and granulocytes in this study were treated with TNF- α or vehicle. The library preparation method in this study was ribosomal depletion to sequence all long RNAs, while Welch 2017 (Mark Welch *et al.* 2017) used poly-A enrichment to sequence mRNA only. 'Reads sequenced' indicate the total number of paired-end reads generated per library. 'Reads mapped' indicate the number of read pairs aligned to the human genome with STAR (Dobin *et al.* 2013). 'Reads assigned' indicates the number of mapped reads assigned to genomic features (e.g., protein coding gene, non-coding RNA) with featureCounts (Liao *et al.* 2014).

Data source	Library type	Differentiation agent	Cell type	Treatment	Replicate	Reads sequenced	Reads mapped	Reads assigned
New data	Total	None	Promyelocyte	None	1	51,259,672	48,256,979	31,775,702
					2	45,409,486	43,088,708	26,931,181
					3	47,722,497	45,321,199	28,412,920
New data	Total	None	Promyelocyte	TNF	1	45,401,741	42,548,543	26,121,834
					2	46,622,711	44,003,082	28,053,460
					3	52,842,736	50,124,478	31,895,061
New data	Total	ATRA	Granulocyte	None	1	46,965,601	44,427,313	24,592,785
					2	53,329,425	50,564,062	28,655,822
					3	52,544,954	49,873,305	28,687,969
New data	Total	ATRA	Granulocyte	TNF	1	44,130,932	41,753,860	23,800,117
					2	55,591,032	52,524,970	29,318,607
					3	44,662,624	42,149,334	22,829,189
Welch 2017	mRNA	None	Promyelocyte	None	1	78,330,794	72,778,198	63,063,700
					2	79,840,457	74,010,895	63,896,640
					3	92,276,843	85,870,266	77,717,651
					4	71,908,445	67,034,452	61,274,376
Welch 2017	mRNA	ATRA	Granulocyte	None	1	78,215,359	73,037,649	63,738,330
					2	79,385,831	73,007,606	65,788,452
					3	67,293,855	61,810,327	55,209,128
					4	74,792,543	68,660,444	61,293,657
Welch 2017	mRNA	TPA	Macrophage	None	1	78,936,655	72,842,622	63,297,008
					2	75,555,764	69,802,997	59,853,678
					3	75,679,506	69,532,640	63,186,748
					4	70,096,915	65,311,735	59,900,363

Dobin, A., C. A. Davis, F. Schlesinger, J. Drenkow, C. Zaleski *et al.* 2013 STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29: 15–21.

Liao, Y., G. K. Smyth, and W. Shi, 2014 featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* 30: 923–930.

Mark Welch, D. B., A. Jauch, J. Langowski, A. L. Olins, and D. E. Olins, 2017 Transcriptomes reflect the phenotypes of undifferentiated, granulocyte and macrophage forms of HL-60/S4 cells. *Nucleus* 8: 222–237.

Single-stranded cDNA was synthesized from 1 μ g of RNA using a High capacity cDNA RT kit (Thermofisher # 4368814), according to the manufacturer's protocol. Real-time quantitative PCR analysis was carried out using predesigned PrimeTime Mini qPCR assays (Integrated DNA Technologies; Supp table 22) on a Lightcycler 480 (Roche). mRNA levels were normalized using reference genes (*GAPDH* and *COX4II*). Log₂ fold changes, standard errors, and confidence intervals were calculated in RStudio (RStudio 2016; R Core 2018) using the delta-delta Ct method (Schmittgen and Livak 2008).

Data availability

TNF- α treatment RNA-seq data are available on GEO, accession GSE120579. Differentiation RNA-seq data from [30] is publicly available on NCBI, <http://www.ncbi.nlm.nih.gov/bioproject/303179>. Analysis of processed RNA-seq data are available on github, https://github.com/jacel/TNF_HL60_S4. Supplemental material available at Figshare: <https://doi.org/10.25387/g3.8146097>.

RESULTS

In order to investigate transcriptional responses to TNF- α , the promyelocytic cell line HL-60/S4 was differentiated into a granulocytic form by treatment with ATRA for 96 hr, as described previously (Jacobson *et al.* 2018b). Both undifferentiated (promyelocytic) and differentiated (granulocytic) cells were treated with 16ng/mL TNF- α

in calcium supplemented media for two hours. TNF- α treatment of promyelocytes and granulocytes were run as independent experiments; as a consequence, analysis of transcriptional changes following differentiation was not appropriate. However, a recently published study investigated transcriptional changes following differentiation of promyelocytic HL-60/S4 cells into granulocytes or macrophages (Mark Welch *et al.* 2017). We reanalyzed this data for use in comparisons with the TNF- α response. All genes in both sets of data that were significantly differentially expressed (False discovery rate adjusted p-value (FDR)<0.05) following differentiation or TNF- α treatment were identified (Supp table 1). In order to assess the reproducibility of our data, a subset of differentially expressed genes (*TNF*, *CDK1*, *VCAM1*) were analyzed by RT-qPCR qPCR in a set of independent samples treated as above *i.e.*, \pm 1 μ M ATRA and \pm 16ng/mL TNF- α (Supp table 2). Consistent with RNA-seq analysis, RT-qPCR demonstrated that TNF- α stimulated promyelocytes and granulocytes have increased levels of *TNF* and *VCAM1*. *CDK1* increases expression in promyelocytes and decreases expression in granulocytes following TNF- α treatment.

Gene expression changes After TNF- α treatment of promyelocytic and granulocytic cells

RNA-seq libraries were aligned using an ultrafast universal RNA-seq aligner (STAR (Dobin *et al.* 2013)) and assigned to genes with featureCounts (Liao *et al.* 2014). DESeq2 (Love *et al.* 2014) was used to filter

out lowly-expressed genes and performing differential expression analysis. 14,420 genes were analyzed for TNF- α dependent differential expression in promyelocytes. 21,305 genes were analyzed for TNF- α dependent differential expression in granulocytes. Principal component analysis of variance stabilized transcripts confirmed clustering by treatment (Supp figure 1).

The promyelocytic and granulocytic forms of HL-60/S4 cells both exhibited strong transcriptional responses to TNF- α treatment (Supp table 1). In promyelocytes, 1,312 genes were significantly increased and 980 significantly decreased (FDR adjusted p value < 0.05, Figure 1A). TNF- α treatment of granulocytes significantly increased expression of 3809 genes and decreased expression of 3,597 genes (FDR adjusted p value < 0.05, Figure 1B). Notably, the granulocytic form had more than three times the number of significantly differentially expressed genes (Figure 1C). Despite this, there was significant overlap in the TNF- α dependent transcriptional response between the granulocytic and promyelocytic cells (2.5-fold more than expected by chance, $P < 1 \times 10^{-5}$, bootstrapping). The TNF- α treatment resulted in more genes being upregulated than downregulated in both the promyelocytic and granulocytic forms of the HL-60/S4 cells ($P < 2 \times 10^{-16}$ and $P = 5 \times 10^{-4}$, respectively; 2-sample test for equality of proportions).

Genes that were significantly differentially expressed after TNF- α treatment in both the promyelocytic and granulocytic forms of HL-60/S4 cells exhibited strongly correlated log₂ fold changes ($P < 2 \times 10^{-16}$, $R^2 = 0.65$). There was a small subset of differentially expressed genes that exhibited changes in opposite directions in promyelocytes and granulocytes (Figure 1D). Notably, the effect sizes of conserved gene expression changes were similar, with a slope of 1.08. If the observed differences in the numbers of differentially expressed (DE) genes were due to a different magnitude of effect, we would expect to see a correlation in fold change between genes that were differentially expressed in one cell type but not the other. However, the fold change of non-conserved genes did not strongly correlate between cell types (Figure 1E & F, $R^2 = 0.038$, $R^2 = 0.15$).

Collectively these results suggest that the difference in TNF- α responses is not simply due to granulocytic cells showing enhanced regulation of a conserved set of genes, resulting in a greater number that are significantly differentially expressed. Instead, additional sets of genes are changing transcriptional activity in TNF- α treated granulocytes.

Functional analysis of the TNF- α response in promyelocytes and granulocytes

Functional analysis of gene sets is affected by the available gene function information, and the method of enrichment analysis (Huang *et al.* 2009). Therefore, we used multiple annotation sources (*i.e.*, Molecular Signatures Database (MSigDB) hallmark gene sets (Liberzon *et al.* 2015), gene ontology (GO) (Alexa and Rahnenfuhrer 2016), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (Ogata *et al.* 1999)) to interrogate the TNF- α response in HL-60/S4 cells and identify robust enrichment results.

Gene set enrichment analysis of promyelocytes and granulocytes treated With TNF: We first interrogated the global gene expression changes that occurred in the two different cell types after TNF- α treatment. Gene set enrichment analysis (GSEA) is a method that allows analysis of an entire differential expression dataset without using arbitrary significance thresholds (Subramanian *et al.* 2005). Instead, the entire dataset is ranked by log₂ fold change, and terms are considered enriched if they are overrepresented at the top or bottom of the ranked list. This approach allows for a differentiation between functional categories of genes that are upregulated or downregulated after treatment

(Mootha *et al.* 2003), and provides an overview of transcriptional changes.

We performed GSEA of hallmark gene sets (Supp table 3). We found a strong upregulation response to TNF- α , in both the promyelocytic and granulocytic forms of the HL-60/S4 cells, that was characterized by immune and cell death pathways (Figure 2). However, the granulocytic genes that were upregulated were also enriched for terms that included notch signaling and hypoxia. Transcripts associated with WNT and beta-catenin signaling were downregulated in promyelocytes (Figure 2).

As observed in the differentially expressed genes, GSEA showed a strong conserved response with notable divergences between TNF- α stimulated promyelocytes and granulocytes.

Functional analysis of conserved, cell type-specific, and opposite TNF- α responses: In order to further investigate the similarities and differences in the TNF- α response, we grouped the list of analyzed genes based on the direction and significance of the expression change in each cell type. Genes that were differentially expressed following TNF- α treatment were divided into four groups according to the nature of the correlation between the promyelocytic and granulocytic responses: 1) conserved; 2) promyelocyte-specific; 3) granulocyte-specific; and 3) opposite responses (Supp table 1). The first group represents the conserved response, *i.e.*, the genes were significantly differentially expressed in the same direction in both promyelocytic and granulocytic forms of the HL-60/S4 cells. The next two groups represent cell type-specific responses – *i.e.*, genes that were only differentially expressed in either promyelocytes or granulocytes in response to TNF- α treatment. The final group is comprised of the 157 genes that were significantly upregulated in the first cell type and significantly downregulated in the other cell type, or *vice versa*.

Having identified groups of genes that change in a conserved, cell-type specific, and opposite manner, we performed functional enrichment analyses to further investigate the responses to TNF- α in promyelocytes and granulocytes.

A conserved TNF- α response: Genes that exhibited significant changes in the same direction in response to TNF- α treatment in both promyelocytic and granulocytic forms of the HL-60/S4 cells were more frequently upregulated than downregulated (~3:1). Notably, this trend was not maintained for cell type-specific gene expression changes (promyelocyte-specific ~1.2:1, granulocyte-specific ~0.9:1). There were nine enriched MSigDB hallmark gene sets (Liberzon *et al.* 2015) in the conserved response gene set (Figure 3A, Supp table 4), all of which are associated with well described effects of TNF- α stimulation; cytokine signaling, inflammation, and apoptosis. This was broadly consistent with the results of GSEA (Figure 2). The top three enriched pathways within KEGG were: NFKB Signaling, NOD-like receptor signaling, and TNF- α signaling pathways (Supp table 5). The top 10 enriched GO terms included interferon-gamma (IFN γ)-mediated signaling pathway, inflammatory response, and positive regulation of I-kappaB kinase/NFKB signaling (Supp table 6).

In summary, using three different annotation databases and four different analysis approaches, we have shown that TNF- α treatment of both promyelocytic and granulocytic forms of HL-60/S4 cells induces a transcription profile associated with inflammatory responses and NFKB signaling.

Granulocyte-specific TNF- α responses: The cell type-specific promyelocytic DE genes had no significant enrichments of MSigDB gene sets, KEGG pathways, or GO terms. Cell type-specific granulocytic DE genes were enriched for MSigDB sets related to cell cycle and energetics (Figure 3B, Supp table 7). The top five enriched KEGG pathways included Cell Cycle, Protein processing in endoplasmic reticulum, and




Figure 1 Transcriptional changes in promyelocytic and granulocytic (+ATRA) forms of HL-60/S4 following two hours of TNF- α treatment (+TNF). A) The Log₂ fold change (log₂FC) and adjusted p values of all analyzed genes in promyelocytes with and without TNF- α treatment. B) The log₂FC and adjusted p values of all analyzed genes in granulocytes with and without TNF- α treatment. C) There is a shared and unique transcriptional response to TNF- α treatment of HL-60/S4 promyelocytes and granulocytes. D) The log₂FC of genes that were significantly differentially expressed in both HL-60/S4 and HL-60/S4+ATRA cells were positively correlated ($R^2 = 0.65$). However, there was a small subset of genes that were anticorrelated. E) The log₂FC of genes that were only differentially expressed in HL-60/S4 cells did not correlate between HL-60/S4 and HL-60/S4+ATRA after TNF- α treatment ($R^2 = 0.04$). F) The log₂FC of genes that were only differentially expressed in HL-60/S4+ATRA cells did not correlate between HL-60/S4 and HL-60/S4+ATRA after TNF- α treatment ($R^2 = 0.15$).

Cellular senescence (Supp table 8). The six enriched GO terms included cell division, G2/M transition of mitotic cell cycle, protein poly- and de-ubiquitination, and neutrophil degranulation (Supp table 9). Thus, granulocytes, but not promyelocytes, exhibited transcriptional changes in genes involved in cell cycle and protein processing in response to TNF- α treatment.

Opposite TNF- α responses in promyelocytes and granulocytes: Genes that were significantly differentially expressed in opposite directions in promyelocytes and granulocytes were enriched for G2M

checkpoint and E2F targets within the MSigDB database (Figure 3C, Supp table 10). Differentially expressed genes in these sets were upregulated in promyelocytes and downregulated in granulocytes, with the exception of *E2F2*. *CDK1* is included in both of these cell-cycle associated gene sets, and is considered sufficient to drive the mammalian cell cycle (Santamaría *et al.* 2007). As described above, the upregulation and downregulation of *CDK1* in promyelocytes and granulocytes respectively was confirmed by RT-qPCR (Supp table 2). The set of genes that was significantly expressed in opposite directions was also enriched for




Figure 2 Transcriptional changes in promyelocytes and granulocytes (+ATRA) treated with TNF (+TNF). Gene set enrichment analysis (GSEA) of genes represented in the MSigDB Hallmark gene sets [1]. All represented genes were ranked by log₂FC, with no significance cutoff. The x axis shows significantly enriched gene sets (FDR < 0.05). The normalized enrichment score (y axis) indicates whether a given gene set was overrepresented for transcripts that exhibited large fold changes. Predicted gene sets (e.g., TNFA signaling via NFKB, p53 pathway, and IFN γ response) were enriched in both conditions. No gene sets were enriched in promyelocytes but not granulocytes. Six gene sets (adipogenesis, estrogen response early and late, hypoxia, IFN α response, and xenobiotic metabolism) were enriched in granulocytes, but not promyelocytes.

three terms, including mitotic chromosome condensation, within the GO database (Supp table 11). There was no enrichment for pathways within KEGG.

The inflammatory effects of TNF- α stimulation are shared by promyelocytes, but cell cycle repression and altered protein metabolism are TNF- α responses specific to granulocytes.

Granulocytic differentiation increases transcript levels of TNF and TNF receptors

We set out to investigate how differentiation into the granulocytic form could modulate the TNF- α response, and identify similarities in the transcriptional changes that occur during differentiation and acute TNF- α treatment. We were unable to analyze transcriptional changes that occurred during differentiation, as promyelocytic and granulocytic cells were treated with TNF- α in separate experiments. In order to assess gene expression changes associated with differentiation we analyzed publicly available RNA-seq data of HL-60/S4 cells differentiated into granulocytes (with ATRA) and macrophages (with TPA). Principal component analysis of variance stabilized transcripts confirmed clustering by differentiation status (Supp figure 1C).

Consistent with previous reports (Mark Welch *et al.* 2017), this analysis confirmed that *TNF* expression was upregulated during differentiation into either granulocytic or macrophage forms of HL-60/S4 cells. The magnitude of *TNF* transcript upregulation was different in granulocytes (log₂ fold change = 1.37) and macrophages (log₂ fold change = 4.08) (Supp table 1). Differentiation also induced changes in the expression levels of the TNFRs. Consistent with previous observations (Mark Welch *et al.* 2017), *TNFRSF1A* gene expression was increased (log₂ fold change = 0.87) after ATRA treatment, but there was no significant change in expression following TPA treatment. By

contrast, *TNFRSF1B* gene expression was increased in both conditions (log₂ = 1.59 and 3.30 following ATRA and TPA treatment, respectively). This observed increase in mRNA expression of *TNF* and both TNF- α receptors may be one explanation for why granulocytes have an enhanced transcriptional response to TNF- α , compared to promyelocytes.

We investigated whether TNF-associated genes were enriched for transcriptional changes associated with differentiation into the granulocytic or macrophage form. We performed a GSEA of the transcriptional changes associated with differentiation into the granulocytic and macrophage form (Figure 4). As described previously, genes associated with cell-cycle terms (e.g., *MYC* targets and G2M checkpoint) were downregulated, while genes associated with inflammatory terms (e.g., IFN γ response, inflammatory response, and indeed TNF- α signaling via NFKB) were upregulated in both differentiation experiments (Figure 4).

As shown in Welch *et al.* (Mark Welch *et al.* 2017), differentiation into either the granulocytic or macrophage form resulted in higher inflammatory gene expression and lower cell cycle rate.

TNF- α treatment has more shared responses with TPA treatment than ATRA treatment

TNF- α treatment interacts with ATRA to augment differentiation of myeloid cells (Bruserud 2000; Witcher *et al.* 2003), but whether it enhances the differentiation into granulocytic cells or modifies the differentiation trajectory is unclear. We compared the transcriptional changes of TNF- α treated granulocytes with those associated with differentiation into granulocytes or macrophages.

Gene sets upregulated in TNF- α stimulated granulocytes and differentiated granulocytes or macrophages were enriched for ontological terms associated with hypoxia and xenobiotic metabolism. Notably,




Figure 3 Gene set overrepresentation in differential expression subsets of TNF- α (+TNF) treated promyelocytes and granulocytes (+ATRA). A) Genes that were significantly differentially expressed in the same direction after TNF- α treatment were overrepresented in several gene sets canonically associated with TNF- α response. B) Genes that were only significantly differentially expressed in granulocytes were overrepresented in 9 gene sets, including 4 cell cycle associated gene sets. They were also overrepresented in the reactive oxygen species pathway, a neutrophilic response to TNF- α . C) Genes that were significantly differentially expressed in opposite directions were overrepresented in two cell-cycle associated gene sets. All differentially expressed hallmark G2M checkpoint genes were upregulated in promyelocytes, and downregulated in granulocytes cells, with the exception of E2F2, a transcription factor that promotes quiescence by binding to promoters and transcriptionally repressing cell cycle genes [2]. All differentially expressed E2F target genes were upregulated in promyelocytes, and downregulated in granulocytes.

genes that were upregulated in promyelocytes treated with TNF- α did not show enrichment for these ontological terms. Notch signaling was upregulated only after TNF-treatment of promyelocytes or differentiation into macrophages. Intriguingly, both early and late estrogen response genes were upregulated in granulocytes treated with TNF- α , and macrophages, despite reports that TNF- α acts to oppose estrogen signaling in breast cancer (Lee and Nam 2008). Four terms were upregulated after TNF- α treatment of granulocytes and differentiation into macrophages: IL2 stat5 signaling, epithelial mesenchymal transition, apical junction, and KRAS signaling (genes downregulated by KRAS activation) (Figure 4).

To further compare the transcriptional changes that occur during differentiation into different cell types with the effects of TNF- α treatment, we assigned differentiation associated changes into four groups: 1) conserved; 2) granulocyte-specific; 3) macrophage-specific; and 4) opposite, *i.e.*, significantly upregulated in granulocytes and significantly downregulated in macrophages, or vice versa (Supp table 1). The first group consists of genes that significantly change expression levels in the same direction after differentiation into either the granulocytic form with ATRA, or the macrophage form with TPA. The

second and third groups contain genes that are differentially expressed only after differentiation into granulocytes or macrophages, but not both. The fourth group represents genes that are differentially expressed after differentiation into granulocytes and macrophages, but are upregulated in granulocytes and downregulated in macrophages, or vice versa. We analyzed these groups of genes for enrichment of MSigDB gene sets, KEGG pathways, and GO terms. GSEA identified the response that is conserved during differentiation into granulocytes or macrophages as being characterized by pro-inflammatory cytokine associated gene sets (*i.e.*, IFN α response, IFN γ response, TNF- α signaling via NFKB), and cell cycle associated gene sets (*i.e.*, G2M checkpoint, MYC targets, and mitotic spindle) (Figure 5A). This finding was consistent with what was observed as being enriched within the KEGG pathways and GO terms (Supp table 13,14).

Genes that changed expression after differentiation into granulocytes, but not macrophages, were not enriched for MSigDB gene sets or GO terms, but they were enriched for three KEGG pathways related to protein processing (Protein processing in endoplasmic reticulum, ubiquitin mediated proteolysis, and proteasome; Supp table 15). In




Figure 4 Transcriptional changes in promyelocytes differentiated into granulocytes with ATRA or macrophages with TNF- α , compared to TNF- α treatment of promyelocytes and granulocytes. Gene set enrichment analysis (GSEA) of genes represented in the MSigDB Hallmark gene sets [1]. All represented genes were ranked by Log2FC, with no significance cutoff. The x axis shows significantly enriched gene sets (FDR < 0.05), and the y axis is calculated from the proportion of genes in the leading edge out of the number of ranked genes, and out of the gene set size. All conditions were associated with upregulated inflammatory gene sets, and both differentiation conditions were associated with downregulation of cell cycle gene sets.

contrast, genes that changed expression after differentiation into macrophages, but not granulocytes, were enriched for several MSigDB gene sets related to cell cycle (Figure 5B, Supp table 16). Enriched KEGG pathways included metabolism and protein processing (*i.e.*, carbon metabolism and protein processing in endoplasmic reticulum), and the TNF- α signaling pathway (Supp table 17). Enriched GO terms included cell division, and terms related to RNA and protein regulation (*i.e.*, regulation of transcription, DNA-templated, translational initiation).

Convergence of transcriptional programs in macrophages and TNF-treated granulocytes: There are many similarities between the behaviors of HL-60/S4 cells differentiated into granulocytes and macrophages. However, there are also notable behavioral differences that include macrophages exhibiting a decreased cell cycle rate, increased survival, and adhesion to both surfaces and other cells (Mark Welch *et al.* 2017).

We investigated the genes that were significantly differentially expressed with negatively correlated log2 fold changes after differentiation into granulocytes or macrophages – *i.e.*, in opposite directions. This gene set was enriched for the IL2/STAT5 signaling, p53 pathway, and TNF- α signaling MSigDB hallmark terms (Figure 5C). 91% of these genes (102/112) increased expression after macrophage differentiation, and decreased expression after granulocytic differentiation. 65% of these genes (70/112) significantly increased expression in granulocytes treated with TNF- α , while only 10% (12/112) significantly decreased expression (Figure 5C). Six transcription factors (*ATF3*, *BCL6*, *FOSL1*, *KLF4*, *KLF9*, *NR4A1*) increased expression after macrophage

differentiation and granulocytes treated with TNF- α , but decreased expression after granulocytic differentiation, which indicates a shared change in transcriptional programming. *CD83*, which is a marker of transdifferentiation of neutrophils into a dendritic-type cell, increased in both TNF- α treated cell types (Iking-Konert *et al.* 2001, 2002). Given that macrophages and dendritic cells are phenotypically similar (Hume 2008; Hashimoto *et al.* 2011), *CD83* could be considered a marker of macrophage transdifferentiation.

Collectively our analyses suggest that TNF- α alters the transcriptional profile in HL-60/S4 cells consistent with a transition from a granulocytic to macrophage phenotype. Consistent with previous observations (Bruserud 2000; Witcher *et al.* 2003), TNF- α modifies the differentiation trajectory away from the ATRA induced granulocytic phenotype, toward a macrophage-like phenotype.

DISCUSSION

TNF- α treatment causes dramatic changes in the transcriptional programs of both promyelocytic and granulocytic HL-60/S4 cells. In this study we found that ATRA and TPA directed differentiation or TNF- α treatment of differentiated HL-60/S4 cells resulted in canonical TNF- α responses involving NFKB signaling, inflammatory signaling, p53 and apoptosis. Due to the reduced proliferation of granulocytic HL-60/S4 cells (Mark Welch *et al.* 2017) we expected differential cell cycle effects of TNF- α treatment (Darzynkiewicz *et al.* 1984; Baxter *et al.* 1999). Previous work has shown increased proliferation in quiescent cells, while proliferating cells exhibited increased apoptosis after TNF- α treatment (Baxter *et al.* 1999). In contrast, we saw evidence of cell cycle




Figure 5 Gene set overrepresentation in differential expression subsets of promyelocytes differentiated into granulocytes or macrophages. A) Genes that were significantly differentially expressed in the same direction after differentiation were overrepresented in gene sets associated with inflammatory signaling and cell cycle. B) Genes that were only significantly differentially expressed in cells differentiated into macrophages with TPA were predominantly associated with cell cycle. C) Genes that were significantly differentially expressed in opposite directions were overrepresented in 3 gene sets: IL2 STAT5 signaling, p53 pathway, and TNF- α signaling via NFKB. A majority of genes in all categories increased expression after macrophage differentiation and in granulocytes treated with TNF- α , and decrease expression after granulocytic differentiation. Non-significant changes are indicated with gray. Point colour in (A) and (B) indicate the FDR adjusted p-value.

repression in granulocytes, particularly at mitotic entry, while proliferating promyelocytes had an increase in cell cycle progression markers such as *CDK1* (Santamaria *et al.* 2007).

There are several factors that could explain the different responses of promyelocytes and granulocytes to TNF- α . First, granulocytes have increased levels of endogenous TNF- α production. Not only does this increase the total TNF- α the cells are exposed to, but endogenously produced TNF- α is membrane-bound prior to processing (Horiuchi *et al.* 2010). The transmembrane and soluble forms of TNF- α have different effects (Kadjani *et al.* 2017), possibly due to the activation of different TNFRs. Membrane-bound TNF- α can activate both TNFR1 (*TNFRSF1A*) and TNFR2 (*TNFRSF1B*), but soluble TNF- α can only activate TNFR1 (Grell *et al.* 1995). Granulocytic cells have higher levels of endogenous TNF expression (therefore, likely higher levels of transmembrane TNF- α) and concurrently higher levels of both *TNFRSF1A*

and *TNFRSF1B* gene expression (Theilgaard-Mönch *et al.* 2005). It has been previously proposed that increased levels of TNFR2 in granulocytic HL-60 cells explain their resistance to TNF- α induced apoptosis (Vondráček *et al.* 2001). Thus, it may be not just the increased levels of receptors, but the ratio of TNFR1 to TNFR2 that determines the ultimate response to TNF- α .

The TNFR1 and TNFR2 receptors have uniquely stimulated pathways (Maney *et al.* 2014; Siegmund *et al.* 2016), however, the two receptors also interact to produce a context specific TNF- α response (Defer *et al.* 2007; Naudé *et al.* 2011). Therefore, manipulating exogenous and endogenous levels of TNF- α or changing the ratio of the TNFR1 and TNFR2 receptors will provide greater insight into the phenotypic consequences of TNF- α treatment. Based on our data, we predict a dose dependent effect of total TNF- α on gene expression, whereby a low level of TNF- α is sufficient to induce regulation of the

set of genes seen in the promyelocyte response, while higher levels of TNF- α are required to repress cell cycle. However, cell cycle repression likely also requires the presence of additional factors (e.g., TNFR-associated factors (Wicovsky *et al.* 2009)) that are expressed during differentiation of the HL-60/S4 cells into the granulocytic form.

A reduction in the expression of cell cycle genes at the population level indicates a change in the proportion of cells at different stages of the cell cycle. Due to the massive transcriptional changes that occur during the progression through cell cycle (Peña-Díaz *et al.* 2013; Boström *et al.* 2017; Liu *et al.* 2017a, 2017b), this may obscure other gene regulatory programs that are associated with alterations to cell function. Despite this limitation, we found evidence of a subset of TNF- α -regulated genes that were upregulated in TNF-treated granulocytes and following macrophage differentiation, but downregulated after granulocytic differentiation. These genes encoded a suite of transcription factors, and the dendritic cell surface marker CD83. Neutrophils that take on characteristics of antigen-presenting cells are often characterized by increased levels of CD83 (Iking-Konert *et al.* 2001, 2002), suggesting that TNF- α may be stimulating transdifferentiation. This is not unprecedented, as there is evidence that neutrophils have phenotypic plasticity (Takashima and Yao 2015), and that TNF- α can stimulate transdifferentiation (Bachem *et al.* 1993; Li *et al.* 2011; Nishikawa *et al.* 2013). However, further functional characterization of TNF- α -treated granulocytic HL-60/S4 cells is required to confirm this hypothesis.

A large-scale TNF- α response experiment treating many different cell types at various stages of differentiation would allow a network analysis of the transcriptional responses and annotation-free pathway discovery (Lu *et al.* 2017; Liu *et al.* 2018). This would provide data to test our hypothesis that total TNF- α exposure correlates with repressive effects on the cell cycle. If this experiment were performed with single cell RNA-sequencing it would also enable the investigation of how individual TNF- α responses result in population-wide changes in cell cycle gene expression. For instance, do all cells respond to TNF- α stimulation with cytokine production, G2/M arrest, and apoptosis, or is there a heterogeneous response between different cells in a population? Moreover, single cell data would allow us to adjust for the cell cycle transcriptional effects, and identify differences that were previously masked by the population structure of unsynchronized cells.

Despite being one of the most highly studied genes in the human genome (Dolgin 2017), the complex signaling (Sedger and McDermott 2014) and context dependent effects (Darzynkiewicz *et al.* 1984; Rauer *et al.* 2011; Siegmund *et al.* 2016) of TNF- α mean that much of its biology remains unknown. With the increasing accessibility of modern sequencing technologies and gene editing, high-throughput investigations of the TNF- α response and signaling will yield new results that enable the contextualization of TNF- α in cancer and immunology.

CONCLUSION

HL-60/S4 cells show a conserved set of core responses to TNF- α treatment irrespective of the differentiation state of the cell. This is expected, since functional annotations represent canonical pathways and responses. However, granulocytes are more responsive to TNF- α , possibly due to priming from increased endogenous TNF expression, and increased levels of TNF- α receptors. Transcriptional changes indicate that TNF- α treatment represses cell cycle progression in granulocytes, but has the opposite effect on promyelocytes. This effect may be sensitive to the sum total of the exogenous and endogenous TNF- α levels. Finally, comparisons of transcriptional changes during differentiation and TNF- α treatment suggest that TNF- α treatment of granulocytes pushes them toward a macrophage transcriptional program. The context specific effects of TNF- α are likely mirrored in other models of

innate immune signaling, and may contribute to the disparities seen between *in vitro* and *in vivo* studies of innate immune signaling.

ACKNOWLEDGMENTS

The authors would like to thank Peter Shepherd and the members of the JMO lab group for comments and discussion.

LITERATURE CITED

- Ajibade, A. A., H. Y. Wang, and R.-F. Wang, 2013 Cell type-specific function of TAK1 in innate immune signaling. *Trends Immunol.* 34: 307–316. <https://doi.org/10.1016/j.it.2013.03.007>
- Alexa, A., and J. Rahnenfuhrer, 2016 topGO: Enrichment analysis for gene ontology. *Bioinformatics* 32: 132–142. <https://doi.org/10.1093/bioinformatics/btt033>
- Annibaldi, A., and P. Meier, 2018 Checkpoints in TNF-induced cell death: implications in inflammation and cancer. *Trends Mol. Med.* 24: 49–65. <https://doi.org/10.1016/j.molmed.2017.11.002>
- Bachem, M. G., K. M. Sell, R. Melchior, J. Kropf, T. Eller *et al.*, 1993 Tumor necrosis factor alpha (TNF alpha) and transforming growth factor beta 1 (TGF beta 1) stimulate fibronectin synthesis and the transdifferentiation of fat-storing cells in the rat liver into myofibroblasts. *Virchows Arch. B Cell Pathol. Incl. Mol. Pathol.* 63: 123–130. <https://doi.org/10.1007/BF02899251>
- Baxter, G. T., R. C. Kuo, O. J. Jupp, P. Vandenabeele, and D. J. MacEwan, 1999 Tumor necrosis factor-alpha mediates both apoptotic cell death and cell proliferation in a human hematopoietic cell line dependent on mitotic activity and receptor subtype expression. *J. Biol. Chem.* 274: 9539–9547. <https://doi.org/10.1074/jbc.274.14.9539>
- Boström, J., Z. Sramkova, A. Salašová, H. Johard, D. Mahdessian *et al.*, 2017 Comparative cell cycle transcriptomics reveals synchronization of developmental transcription factor networks in cancer cells. *PLoS One* 12: e0188772. <https://doi.org/10.1371/journal.pone.0188772>
- Bruserud, Ø., 2000 New strategies for the treatment of acute myelogenous leukemia: Differentiation induction - present use and future possibilities. *Stem Cells* 18: 157–165. <https://doi.org/10.1634/stemcells.18-3-157>
- Chowers, Y., and M. Allez, 2010 Efficacy of anti-TNF in Crohn's disease: how does it work? *Curr. Drug Targets* 11: 138–142. <https://doi.org/10.2174/138945010790309876>
- Chu, C. Q., M. Field, M. Feldmann, and R. N. Maini, 1991 Localization of Tumor Necrosis Factor α in synovial tissues and at the Cartilage-Pannus Junction in patients with rheumatoid arthritis. *Arthritis Rheum.* 34: 1125–1132. <https://doi.org/10.1002/art.1780340908>
- Darzynkiewicz, Z., B. Williamson, E. A. Carswell, and L. J. Old, 1984 Cell cycle-specific effects of tumor necrosis factor. *Cancer Res.* 44: 83–90.
- Defer, N., A. Azroyan, F. Pecker, and C. Pavoiné, 2007 TNFR1 and TNFR2 signaling interplay in cardiac myocytes. *J. Biol. Chem.* 282: 35564–35573. <https://doi.org/10.1074/jbc.M704003200>
- Dobin, A., C. A. Davis, F. Schlesinger, J. Drenkow, C. Zaleski *et al.*, 2013 STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29: 15–21. <https://doi.org/10.1093/bioinformatics/bts635>
- Dolgin, E., 2017 The greatest hits of the human genome: A tour through the most studied genes in biology reveals some surprises. *Nature* 551: 427–431.
- Erwig, L. P., D. C. Kluth, G. M. Walsh, and A. J. Rees, 1998 Initial cytokine exposure determines function of macrophages and renders them unresponsive to other cytokines. *J. Immunol.* 161: 1983–1988.
- Ewels, P., M. Magnusson, S. Lundin, and M. Käller, 2016 MultiQC: Summarize analysis results for multiple tools and samples in a single report. *Bioinformatics* 32: 3047–3048. <https://doi.org/10.1093/bioinformatics/btw354>
- Feldmann, M., 2002 Development of anti-TNF therapy for rheumatoid arthritis. *Nat. Rev. Immunol.* 2: 364–371. <https://doi.org/10.1038/nri802>
- Francisco, N. M., N.-J. Hsu, R. Keeton, P. Randall, B. Sebesho *et al.*, 2015 TNF-dependent regulation and activation of innate immune cells are essential for host protection against cerebral tuberculosis. *J. Neuroinflammation* 12: 125. <https://doi.org/10.1186/s12974-015-0345-1>

- Gallagher, R., S. Collins, J. Trujillo, K. McCredie, M. Ahearn *et al.*, 1979 Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. *Blood* 54: 713–733.
- Grell, M., E. Douni, H. Wajant, M. Löhden, M. Clauss *et al.*, 1995 The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. *Cell* 83: 793–802. [https://doi.org/10.1016/0092-8674\(95\)90192-2](https://doi.org/10.1016/0092-8674(95)90192-2)
- Harrow, J., A. Frankish, J. M. Gonzalez, E. Tapanari, M. Diekhans *et al.*, 2012 GENCODE: The reference human genome annotation for The ENCODE Project. *Genome Res.* 22: 1760–1774. <https://doi.org/10.1101/gr.135350.111>
- Hashimoto, D., J. Miller, and M. Merad, 2011 Dendritic cell and macrophage heterogeneity in vivo. *Immunity* 35: 323–335. <https://doi.org/10.1016/j.immuni.2011.09.007>
- Horiuchi, T., H. Mitoma, S. Harashima, H. Tsukamoto, and T. Shimoda, 2012 Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. *Rheumatology* 49: 1215–1228. <https://doi.org/10.1093/rheumatology/keq031>
- Huang, D. W., B. T. Sherman, and R. A. Lempicki, 2009 Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res.* 37: 1–13. <https://doi.org/10.1093/nar/gkn923>
- Hume, D. A., 2008 Macrophages as APC and the dendritic cell myth. *J. Immunol.* 181: 5829–5835. <https://doi.org/10.4049/jimmunol.181.9.5829>
- Iking-Konert, C., C. Csekö, C. Wagner, S. Stegmaier, K. Andrassy *et al.*, 2001 Transdifferentiation of polymorphonuclear neutrophils: acquisition of CD83 and other functional characteristics of dendritic cells. *J. Mol. Med. (Berl.)* 79: 464–474. <https://doi.org/10.1007/s001090100237>
- Iking-Konert, C., C. Wagner, B. Deneff, F. Hug, M. Schneider *et al.*, 2002 Up-regulation of the dendritic cell marker CD83 on polymorphonuclear neutrophils (PMN): divergent expression in acute bacterial infections and chronic inflammatory disease. *Clin. Exp. Immunol.* 130: 501–508. <https://doi.org/10.1046/j.1365-2249.2002.02008.x>
- Jacobson, E. C., R. S. Grand, J. K. Perry, M. H. Vickers, A. L. Olins *et al.*, 2019 Hi-C detects novel structural variants in HL-60 and HL-60/S4 cell lines. *Genomics* <https://www.ncbi.nlm.nih.gov/pubmed/31095996>
- Jacobson, E. C., J. K. Perry, D. S. Long, A. L. Olins, D. E. Olins *et al.*, 2018b Migration through a small pore disrupts inactive chromatin organization in neutrophil-like cells. *BMC Biol.* 16: 142. <https://doi.org/10.1186/s12915-018-0608-2>
- Kadrijani, A. A., H. A. Aghdaei, D. Sorrentino, A. Mirzaei, S. Shahrokh *et al.*, 2017 Transmembrane TNF- α density, but not soluble TNF- α level, is associated with primary response to infliximab in inflammatory bowel disease. *Clin. Transl. Gastroenterol.* 8: e117. <https://doi.org/10.1038/ctg.2017.44>
- Kagoya, Y., A. Yoshimi, K. Kataoka, M. Nakagawa, K. Kumano *et al.*, 2014 Positive feedback between NF- κ B and TNF- α promotes leukemia-initiating cell capacity. *J. Clin. Invest.* 124: 528–542. <https://doi.org/10.1172/JCI68101>
- Kalb, A., H. Bluethmann, M. W. Moore, and W. Lesslauer, 1996 Tumor necrosis factor receptors (Tnfr) in mouse fibroblasts deficient in Tnfr1 or Tnfr2 are signaling competent and activate the mitogen-activated protein kinase pathway with differential kinetics. *J. Biol. Chem.* 271: 28097–28104. <https://doi.org/10.1074/jbc.271.45.28097>
- Kim, E. K., and E.-J. Choi, 2010 Pathological roles of MAPK signaling pathways in human diseases. *Biochim. Biophys. Acta.* 1802: 396–405. <https://doi.org/10.1016/j.bbadis.2009.12.009>
- Lee, S.-H., and H.-S. Nam, 2008 TNF alpha-induced down-regulation of estrogen receptor alpha in MCF-7 breast cancer cells. *Mol. Cells* 26: 285–290.
- Li, B., A. Pozzi, and P. P. Young, 2011 TNF accelerates monocyte to endothelial transdifferentiation in tumors by the induction of integrin 5 expression and adhesion to fibronectin. *Mol. Cancer Res.* 9: 702–711. <https://doi.org/10.1158/1541-7786.MCR-10-0484>
- Liao, Y., G. K. Smyth, and W. Shi, 2014 featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* 30: 923–930. <https://doi.org/10.1093/bioinformatics/btt656>
- Liberzon, A., C. Birger, H. Thorvaldsdóttir, M. Ghandi, J. P. Mesirov *et al.*, 2015 The molecular signatures database hallmark gene set collection. *Cell Syst.* 1: 417–425. <https://doi.org/10.1016/j.cels.2015.12.004>
- Liu, Y., S. Chen, S. Wang, F. Soares, M. Fischer *et al.*, 2017a Transcriptional landscape of the human cell cycle. *Proc. Natl. Acad. Sci. USA* 114: 3473–3478. <https://doi.org/10.1073/pnas.1617636114>
- Liu, Z., H. Lou, K. Xie, H. Wang, N. Chen *et al.*, 2017b Reconstructing cell cycle pseudo time-series via single-cell transcriptome data. *Nat. Commun.* 8: 22. <https://doi.org/10.1038/s41467-017-00039-z>
- Liu, Z., J. Meng, X. Li, F. Zhu, T. Liu *et al.*, 2018 Identification of hub genes and key pathways associated with two subtypes of diffuse large B-cell lymphoma based on gene expression profiling via integrated bioinformatics. *BioMed Res. Int.* 2018: 1–14.
- Love, M. I., W. Huber, and S. Anders, 2014 Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 15: 550. <https://doi.org/10.1186/s13059-014-0550-8>
- Lu, X., J. Lu, B. Liao, X. Li, X. Qian *et al.*, 2017 Driver pattern identification over the gene co-expression of drug response in ovarian cancer by integrating high throughput genomics data. *Sci. Rep.* 7: 16188. <https://doi.org/10.1038/s41598-017-16286-5>
- Maney, N. J., G. Reynolds, A. Krippner-Heidenreich, and C. M. U. Hilkens, 2014 Dendritic cell maturation and survival are differentially regulated by TNFR1 and TNFR2. *J. Immunol.* 193: 4914–4923. <https://doi.org/10.4049/jimmunol.1302929>
- Mark Welch, D. B., A. Jauch, J. Langowski, A. L. Olins, and D. E. Olins, 2017 Transcriptomes reflect the phenotypes of undifferentiated, granulocyte and macrophage forms of HL-60/S4 cells. *Nucleus* 8: 222–237. <https://doi.org/10.1080/19491034.2017.1285989>
- Maxwell, L. J., J. Zochling, A. Boonen, J. A. Singh, M. M. Veras *et al.*, 2015 TNF-alpha inhibitors for ankylosing spondylitis. *Cochrane Database Syst. Rev.* <https://doi.org/10.1002/14651858.CD005468.pub2>
- Mizger, J. P., M. R. Spieker, and C. M. Doerschuk, 2001 Early response cytokines and innate immunity: essential roles for TNF receptor 1 and type I IL-1 receptor during Escherichia coli pneumonia in mice. *J. Immunol.* 166: 4042–4048. <https://doi.org/10.4049/jimmunol.166.6.4042>
- Mootha, V. K., C. M. Lindgren, K.-F. Eriksson, A. Subramanian, S. Sihag *et al.*, 2003 PGC-1 α -responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat. Genet.* 34: 267–273. <https://doi.org/10.1038/ng1180>
- Naudé, P. J. W., J. A. Den Boer, P. G. M. Luiten, and U. L. M. Eisel, 2011 Tumor necrosis factor receptor cross-talk. *FEBS J.* 278: 888–898. <https://doi.org/10.1111/j.1742-4658.2011.08017.x>
- Nishikawa, Y., M. Sone, Y. Nagahama, E. Kumagai, Y. Doi *et al.*, 2013 Tumor necrosis factor- α promotes bile ductular transdifferentiation of mature rat hepatocytes in vitro. *J. Cell. Biochem.* 114: 831–843. <https://doi.org/10.1002/jcb.24424>
- Ogata, H., S. Goto, K. Sato, W. Fujibuchi, H. Bono *et al.*, 1999 KEGG: Kyoto encyclopedia of genes and genomes. *Nucleic Acids Res.* 27: 29–34. <https://doi.org/10.1093/nar/27.1.29>
- Olarerin-George, A. O., and J. B. Hogenesch, 2015 Assessing the prevalence of mycoplasma contamination in cell culture via a survey of NCBI's RNA-seq archive. *Nucleic Acids Res.* 43: 2535–2542. <https://doi.org/10.1093/nar/gkv136>
- Ozeki, M., and J. E. Shively, 2008 Differential cell fates induced by all-trans retinoic acid-treated HL-60 human leukemia cells. *J. Leukoc. Biol.* 84: 769–779. <https://doi.org/10.1189/jlb.1207817>
- Palucka, A. K., J.-P. Blanck, L. Bennett, V. Pascual, and J. Banchereau, 2005 Cross-regulation of TNF and IFN-alpha in autoimmune diseases. *Proc. Natl. Acad. Sci. USA* 102: 3372–3377. <https://doi.org/10.1073/pnas.0408506102>
- Peña-Diaz, J., S. A. Hegre, E. Anderssen, P. A. Aas, R. Mjelle *et al.*, 2013 Transcription profiling during the cell cycle shows that a subset of Polycomb-targeted genes is upregulated during DNA replication. *Nucleic Acids Res.* 41: 2846–2856. <https://doi.org/10.1093/nar/gks1336>

- Plotnikov, A., E. Zehorai, S. Procaccia, and R. Seger, 2011 The MAPK cascades: Signaling components, nuclear roles and mechanisms of nuclear translocation. *Biochim. Biophys. Acta - Mol. Cell Res.* 1813: 1619–1633. <https://doi.org/10.1016/j.bbamcr.2010.12.012>
- R Core, T., 2018 R: A language and environment for statistical computing. <https://doi.org/10.1038/cddis.2011.78>
- Rauert, H., T. Stühmer, R. Bargou, H. Wajant, and D. Siegmund, 2011 TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms. *Cell Death Dis.* 2: e194. <https://doi.org/10.1038/cddis.2011.78>
- Roberts, N. J., S. Zhou, L. A. Diaz, and M. Holdhoff, 2011 Systemic use of tumor necrosis factor alpha as an anticancer agent. *Oncotarget* 2: 739–751. <https://doi.org/10.18632/oncotarget.344>
- Rowat, A. C., D. E. Jaalouk, M. Zwerger, W. L. Ung, I. A. Eydelnant *et al.*, 2013 Nuclear envelope composition determines the ability of neutrophil-type cells to passage through micron-scale constrictions. *J. Biol. Chem.* 288: 8610–8618. <https://doi.org/10.1074/jbc.M112.441535>
- RStudio, 2016 RStudio: Integrated Development Environment for R.
- Sabio, G., and R. J. Davis, 2014 TNF and MAP kinase signalling pathways. *Semin. Immunol.* 26: 237–245. <https://doi.org/10.1016/j.smim.2014.02.009>
- Santamaría, D., C. Barrière, A. Cerqueira, S. Hunt, C. Tardy *et al.*, 2007 Cdk1 is sufficient to drive the mammalian cell cycle. *Nature* 448: 811–815. <https://doi.org/10.1038/nature06046>
- Schmittgen, T. D., and K. J. Livak, 2008 Analyzing real-time PCR data by the comparative C(T) method. *Nat. Protoc.* 3: 1101–1108. <https://doi.org/10.1038/nprot.2008.73>
- Sedger, L. M., and M. F. McDermott, 2014 TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants – past, present and future. *Cytokine Growth Factor Rev.* 25: 453–472. <https://doi.org/10.1016/j.cytogfr.2014.07.016>
- Shalaby, M. R., A. Waage, L. Aarden, and T. Espevik, 1989 Endotoxin, tumor necrosis factor-alpha and interleukin 1 induce interleukin 6 production in vivo. *Clin. Immunol. Immunopathol.* 53: 488–498. [https://doi.org/10.1016/0090-1229\(89\)90010-X](https://doi.org/10.1016/0090-1229(89)90010-X)
- Siegmund, D., J. Kums, M. Ehrenschwender, and H. Wajant, 2016 Activation of TNFR2 sensitizes macrophages for TNFR1-mediated necroptosis. *Cell Death Dis.* 7: e2375. <https://doi.org/10.1038/cddis.2016.285>
- Smart, S. J., and T. B. Casale, 1994 TNF-alpha-induced transendothelial neutrophil migration is IL-8 dependent. *Am. J. Physiol.* 266: L238–L245.
- Striz, I., E. Brabcova, L. Kolesar, and A. Sekerkova, 2014 Cytokine networking of innate immunity cells: a potential target of therapy. *Clin. Sci. (Lond.)* 126: 593–612. <https://doi.org/10.1042/CS20130497>
- Su, M., S. Alonso, J. W. Jones, J. Yu, M. A. Kane *et al.*, 2015 All-trans retinoic acid activity in acute myeloid leukemia: Role of cytochrome P450 enzyme expression by the microenvironment. *PLoS One* 10: e0127790. <https://doi.org/10.1371/journal.pone.0127790>
- Subramanian, A., P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert *et al.*, 2005 Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA* 102: 15545–15550. <https://doi.org/10.1073/pnas.0506580102>
- Takashima, A., and Y. Yao, 2015 Neutrophil plasticity: acquisition of phenotype and functionality of antigen-presenting cell. *J. Leukoc. Biol.* 98: 489–496. <https://doi.org/10.1189/jlb.1MR1014-502R>
- Theilgaard-Mönch, K., L. C. Jacobsen, R. Borup, T. Rasmussen, M. D. Bjerregaard *et al.*, 2005 The transcriptional program of terminal granulocytic differentiation. *Blood* 105: 1785–1796. <https://doi.org/10.1182/blood-2004-08-3346>
- Ting, A. T., and M. J. M. Bertrand, 2016 More to life than NF-κB in TNFR1 signaling. *Trends Immunol.* 37: 535–545. <https://doi.org/10.1016/j.it.2016.06.002>
- Vieira, S. M., H. P. Lemos, R. Grespan, M. H. Napimoga, D. Dal-Secco *et al.*, 2009 A crucial role for TNF-alpha in mediating neutrophil influx induced by endogenously generated or exogenous chemokines, KC/CXCL1 and LIX/CXCL5. *Br. J. Pharmacol.* 158: 779–789. <https://doi.org/10.1111/j.1476-5381.2009.00367.x>
- Vondráček, J., M. A. Sheard, P. Krejčí, K. Minksová, J. Hofmanová *et al.*, 2001 Modulation of death receptor-mediated apoptosis in differentiating human myeloid leukemia HL-60 cells. *J. Leukoc. Biol.* 69: 794–802.
- Wang, F., B. T. Schwarz, W. V. Graham, Y. Wang, L. Su *et al.*, 2006 IFN-γ-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction. *Gastroenterology* 131: 1153–1163. <https://doi.org/10.1053/j.gastro.2006.08.022>
- Wicovsky, A., F. Henkler, S. Salzmann, P. Scheurich, C. Kneitz *et al.*, 2009 Tumor necrosis factor receptor-associated factor-1 enhances proinflammatory TNF receptor-2 signaling and modifies TNFR1–TNFR2 cooperation. *Oncogene* 28: 1769–1781. <https://doi.org/10.1038/onc.2009.29>
- Wikham, H., 2016 *ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New York.
- Wikham, H., R. François, L. Henry, and K. Müller, 2018 *dplyr: A Grammar of Data Manipulation*.
- Witcher, M., D. T. Ross, C. Rousseau, L. Deluca, and W. H. Miller, 2003 Synergy between all-trans retinoic acid and tumor necrosis factor pathways in acute leukemia cells. *Blood* 102: 237–245.
- Yarilina, A., K.-H. Park-Min, T. Antoniv, X. Hu, and L. B. Ivashkiv, 2008 TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. *Nat. Immunol.* 9: 378–387. <https://doi.org/10.1038/ni1576>
- Yu, G., L.-G. Wang, Y. Han, and Q.-Y. He, 2012 clusterProfiler: an R package for comparing biological themes among gene clusters. *Omi. A J. Integr. Biol.* 16: 284–287. <https://doi.org/10.1089/omi.2011.0118>
- Ziegler-Heitbrock, H. W., A. Möller, R. P. Linke, J. G. Haas, E. P. Rieber *et al.*, 1986 Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity. *Cancer Res.* 46: 5947–5952.

Communicating editor: N. Blouin